NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2023
Voltar para busca
Dado oficial do USPTO
THERAMEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
17
Atualização mais recente
05/12/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
08/09/2022
Data de registro
05/12/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/12/2023
Última transação
05/12/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
99
Localização do titular
Belgravia, London, GB
Examinador
BERNS, LEE ANNE
Unidade examinadora
M90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Theramex HQ UK Limited
Representantes
Leigh Ann Lindquist SUGHRUE MION, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's healthmenopauseosteoporosisuterine fibroidsendometriosisadenomyosismenstrual bleeding disordersfertilityinfertilityassisted reproductive technologyIVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive healthcontraceptionmenstrual bleeding disordersfertilityinfertilityfertility enhancement preparationsassisted reproductive technologyIVFmiscarriage; pharmaceutical preparations and substances for use in relation to contraception; pharmaceutical preparations and substances for use in relation to conceptioncontraceptionmenstrual bleeding disordersfertilityinfertilityfertility enhancement preparationsassisted reproductive technologyIVFmiscarriage; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; Pharmaceutical preparations and substances for the treatment of osteoporosis; Pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; Pharmaceutical preparations and substances for the treatment of cartilage disorders; Pharmaceutical preparations and substances for the treatment of bone disorders; Pharmaceutical preparations and substances for the treatment of bone loss; Pharmaceutical preparations and substances for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of calcium deficiency; Pharmaceutical preparations and substances being calcium regulators; Pharmaceutical preparations and substances for the treatment of Paget's disease; Phosphates for pharmaceutical purposes; Self-injectors sold filled with pharmaceutical preparations for the treatment of infertility for subcutaneous injectionosteoporosis; Vitamin supplements; mineral supplements; calcium supplements; all the above being for human use and none being for dental use or for use in relation to oral hygiene
Publicações
Histórico de despachos e eventos da marca no USPTO.
17 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2023
ISPO
WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
21/09/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
20/09/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/09/2023
PUBO
PUBLISHED FOR OPPOSITION
19/09/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/07/2023
GNRT
NON-FINAL ACTION E-MAILED
06/07/2023
CNRT
NON-FINAL ACTION WRITTEN
06/07/2023
DOCK
ASSIGNED TO EXAMINER
22/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/09/2022
NWAP
NEW APPLICATION ENTERED
12/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace THERAMEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.